Adiponectin circulating levels and 10-year (2002–2012) cardiovascular disease incidence:the ATTICA Study

Kyrou, Ioannis, Tsantarlioti, Olga, Panagiotakos, Demosthenes B., Tsigos, Constantine, Georgousopoulou, Ekavi, Chrysohoou, Christina, Skoumas, Ioannis, Tousoulis, Dimitrios, Stefanadis, Christodoulos, Pitsavos, Christos and the ATTICA study group (2017). Adiponectin circulating levels and 10-year (2002–2012) cardiovascular disease incidence:the ATTICA Study. Endocrine, early , pp. 1-11.

Abstract

Purpose: Adiponectin is an adipokine with anti-inflammatory and cardiovascular-protective properties. Existing epidemiological evidence is conflicting on the exact relationship between adiponectin and long-term cardiovascular disease (CVD) risk. Our aim was to prospectively assess whether circulating adiponectin is associated with long-term incident CVD. Methods: A population-based, prospective study in adults (>18 years) without previous CVD history (ATTICA study). Circulating total adiponectin levels were measured at baseline (2001–2002) in a sub-sample (n = 531; women/men: 222/309; age: 40 ± 11 years) of the ATTICA cohort and complete 10-year follow-up data were available in 366 of these participants (women/men: 154/212; age: 40 ± 12 years). Results: After adjusting for multiple factors, including age, sex, body mass index, waist circumference, smoking, physical activity, Mediterranean diet adherence, hypertension, diabetes, and hypercholesterolemia, our logistic regression analysis indicates that an increase in circulating total adiponectin levels by 1 unit was associated with 36% lower CVD risk (relative risk [RR]: 0.64, 95% confidence interval [CI] 0.42–0.96; p = 0.03). Further adjusting for interleukin-6 plasma levels had no significant impact (RR: 0.60, 95% CI 0.38–0.94; p = 0.03), while additional adjustment for circulating C-reactive protein (CRP) modestly attenuated this association (RR: 0.63, 95% CI 0.40–0.99; p = 0.046). Conclusions: In our study, elevated circulating total adiponectin levels were associated with lower 10-year CVD risk in adults without previous CVD, independently of other established CVD risk factors. This association appeared to be modestly attenuated by CRP, yet was not mediated by interleukin-6 which is the main endocrine/circulating pro-inflammatory cytokine.

Publication DOI: https://doi.org/10.1007/s12020-017-1434-y
Divisions: Aston Medical School
Additional Information: © 2017 Springer International Publishing AG Funding: Hellenic Cardiology Society (HCS2002) and the Hellenic Atherosclerosis Society (HAS2003)
Uncontrolled Keywords: Adiponectin,ATTICA study,Cardiovascular disease,CVD risk,Endocrinology, Diabetes and Metabolism,Endocrinology
Full Text Link:
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
Published Online Date: 2017-10-16
Authors: Kyrou, Ioannis ( 0000-0002-6997-3439)
Tsantarlioti, Olga
Panagiotakos, Demosthenes B.
Tsigos, Constantine
Georgousopoulou, Ekavi
Chrysohoou, Christina
Skoumas, Ioannis
Tousoulis, Dimitrios
Stefanadis, Christodoulos
Pitsavos, Christos
, the ATTICA study group

Download

[img]

Version: Accepted Version

| Preview

Export / Share Citation


Statistics

Additional statistics for this record